(Q41171305)

27 September 2017

1 reference

title

Review of the major intervention trials of lowering coronary artery disease risk through cholesterol reduction (English)

1 reference

27 September 2017

main subject

coronary artery disease

1 reference

R M Stark

1

1 reference

27 September 2017

language of work or name

English

0 references

publication date

1 September 1996

1 reference

American Journal of Cardiology

27 September 2017

published in

1 reference

27 September 2017

volume

78

1 reference

27 September 2017

issue

6A

1 reference

27 September 2017

page(s)

13-19

1 reference

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Lipid Research Clinics Coronary Primary Prevention Trial: results and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

The Helsinki Heart Study: basic design and randomization procedure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Oslo Study Diet and Antismoking Trial. Results after 102 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Cost of prevention. The case of lipid lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900657-1

10.1016/S0002-9149(96)00657-1

7 January 2021

Identifiers

DOI

1 reference

27 September 2017

1 reference